elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q30384301-18F34CCB-8F29-47B6-86B7-A389B1A4D899
Q30384301-18F34CCB-8F29-47B6-86B7-A389B1A4D899
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30384301-18F34CCB-8F29-47B6-86B7-A389B1A4D899
The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response
P2860
Q30384301-18F34CCB-8F29-47B6-86B7-A389B1A4D899
BestRank
Statement
http://www.wikidata.org/entity/statement/Q30384301-18F34CCB-8F29-47B6-86B7-A389B1A4D899
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d188970aa57f77e8f99f2fbbd042c4865b707169
P2860
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.